MedTrace Logo

N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure

NCT00692718 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2008-06-19

No results posted yet for this study

Summary

Our study is to investigate the effect of N-3 Fatty Acids for the prevention of atrial fibrillation in patients with acute heart failure or acute myocardial infarction

Conditions

  • Acute Heart Failure
  • Acute Myocardial Infarction

Interventions

DRUG

Epadel, Eicosapentaenoic acid

Epadel 900mg, 2 times a day, during hospitalization

Sponsors & Collaborators

  • Osaka General Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00692718 on ClinicalTrials.gov